To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

Weight loss from glucagon-like peptide 1 agonists clearly alleviates knee osteoarthritis pain, but other recently published data give pause regarding possible long-term adverse effects.

This partner We recently published a list of 11 Best Performing Energy Stocks So Far In 2025. In this article, we are going to take a look at where Global Partners LP (NYSE:GLP) stands against ...

The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

In recent years, the growing list of medical benefits for GIP and GLP-1 agonists (think Ozempic for diabetes or Zepbound for weight loss, among others) has caused demand to skyrocket ...